Partnering

ASINEX is interested in research, development and commercialization relationships with pharmaceutical and biotechnology companies.

ASINEX has mastered its Compound-to-Target™ platform that facilitates translation of innovative small molecule and macrocyclic chemistry into pre-clinical leads focusing on specific oncogenic pathways:

・ Apoptotic pathway

・ Cyclin-dependent kinase pathways

・ Wnt/β-catenin signaling pathway

In addition to oncology, the platform provides valuable starting points for antibacterial R&D.